Target intelligence / Profile preview

Fungal cell wall and membrane integrity (disruption target) (null)

Target
null
Molecular classification
Other (target class; includes multiple molecular targets), Enzyme (for specific enzymes such as chitin synthase, 1,3-β-D-glucan synthase), Membrane lipid (e.g., ergosterol), Structural component
01

Overview

Fungal cell wall and membrane integrity disruption is a central antifungal mechanism targeting structural components unique to fungi, particularly the β-glucan and chitin polysaccharides of the cell wall, and ergosterol of the cell membrane. Enzymes, antibiotics, and small molecules may act by permeabilizing the plasma membrane, forming pores, inhibiting biosynthetic enzymes, or destabilizing essential membrane sterols. This results in the loss of ion gradients, leakage of cellular contents, and ultimately fungal cell death. Examples include polyenes (which bind ergosterol to form pores), azoles (which block ergosterol biosynthesis), echinocandins (which inhibit β-glucan synthesis), and lytic peptides/enzymes (that degrade cell wall components). While highly effective, these agents may have off-target toxicity and face resistance mechanisms such as target modification or efflux pump overexpression[1][2][3][5][6][7][8][9].

Other names
Disruption of fungal cell wall integrityDisruption of fungal membrane integrityFungal membrane permeabilizationFungal cell envelope disruption
02

Mechanism of action

Disruption of membrane integrity (often via pore formation or membrane destabilization) Inhibition of cell wall biosynthesis (e.g., inhibition of enzymes required for β-glucan or chitin synthesis) Chelation/disruption of essential cofactors for cell wall/membrane biosynthetic enzymes Direct binding to membrane sterols (e.g., ergosterol) Induction of oxidative stress and downstream cell death

03

Biological functions

Cell deathDisruption of cell homeostasisLoss of osmotic balanceInhibition of cell growth
04

Disease associations

InfectionFungal disease
05

Safety considerations

Off-target toxicity (especially for agents that disrupt mammalian cell membranes)Nephrotoxicity (noted for amphotericin B)Emergence of resistance via target modification or efflux mechanismsImmunogenicity of peptide antibiotics
06

Interacting drugs

Azoles (e.g., fluconazole, itraconazole, voriconazole)

7 more in the full profile.

07

Biomarkers

Not well established for the process generally; for specific targets may include ergosterol levels (for polyene/azole sensitivity), β-D-glucan levels, or membrane permeability assays

Beyond the preview

Go deeper on Fungal cell wall and membrane integrity (disruption target) (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fungal cell wall and membrane integrity (disruption target) (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call